v3.26.1
Composition of Certain Balance Sheet Items
 6 Months Ended
Jun. 30, 2026
Balance Sheet Related Disclosures [Abstract]  
Composition of Certain Balance Sheet Items Composition of Certain Balance Sheet Items
Inventory
June 30,
2026		December 31,
2025
 (in thousands)
Raw materials$— $847 
Work in progress18,913 13,703 
Finished goods13,228 9,412 
Total inventory32,141 23,962 
Less strategic inventory classified as non-current(18,956)(11,094)
Total inventory classified as current$13,185 $12,868 
We have purchased and hold significant quantities of active pharmaceutical ingredient (“API”) for our Products, which are included in raw materials and work in progress inventory. We classify inventory we do not expect to utilize within 12 months of the balance sheet date as “strategic inventory,” a non-current asset.
Prior to receiving regulatory approval, we record the cost of manufacturing our product candidates as research and development expense at the time it is incurred. We capitalize manufacturing costs incurred after regulatory approval as inventory.
Prepaid expenses and other current assets
June 30,
2026		December 31,
2025
(in thousands)
Prepaid expenses$17,568 $8,688 
Clinical deposits6,556 5,238 
Prepaid income taxes4,462 14,569 
Deferred clinical materials4,425 5,061 
Other current assets8,363 7,102 
Total prepaid expenses and other current assets$41,374 $40,658 
Accrued and other liabilities
June 30,
2026		December 31,
2025
 (in thousands)
Short-term accrued government rebates$45,854 $35,679 
Accrued compensation38,248 37,400 
Accrued selling and marketing costs16,492 10,610 
Other14,753 6,914 
Total accrued and other liabilities$115,347 $90,603